HealthQuill Articles by: HealthQuill
The global talks on climate finance have broken down due to an impasse on the amount of funding the rich nations are willing to commit to the poor countries and by whom.
Climate Health Pharma

Climate finance talks in Bonn fail as funding rift emerges among nations

The global talks on climate finance have broken down due to an impasse on the amount of funding the rich nations are willing

Read More
https://www.cancer.gov/news-events/press-releases/2024/genetic-factors-predict-x-chromosome-loss
Drugs Health Pharma

Genetic factors may help predict loss of X chromosome in older women

Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood

Read More
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

FDA approves AstraZeneca’s type-2 diabetes drug in US market

AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according

Read More
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
The US drug regulator has granted accelerated approval for a drug to treat chronic inflammatory liver disease to Genfit, headquartered in Nord, France, and Paris-based Ipsen, according to the companies.
Drugs Health Pharma

FDA gives approval for Ispen, Genfit’s drug to treat chronic liver disease

The US drug regulator has granted accelerated approval for a drug to treat chronic inflammatory liver disease to Genfit, headquartered in Nord, France,

Read More
Fifteen member states of the European Union and the European Economic Area will procure up to 40 million doses of avian influenza virus vaccine from CSL Sequris UK Ltd., over a maximum period of four years to prevent the spread or potential outbreaks of bird flu in the region.
Drugs Health Pharma

EU to procure 40 million doses of avian flu vaccine from CSL Seqirus 

Fifteen member states of the European Union and the European Economic Area will procure up to 40 million doses of avian influenza virus

Read More
A four-year-old child in India has been detected with avian influenza A(H9N2) in the Eastern state of West Bengal, the World Health Organization reported.
Drugs Health Pharma

Child in India detected with bird flu in eastern West Bengal state: WHO 

A four-year-old child in India has been detected with avian influenza A(H9N2) in the Eastern state of West Bengal, the World Health Organization

Read More
A 59-year-old person in Mexico died in April after contracting avian influenza A(H5N2) virus, the first such death in the country, according to the World Health Organization.
Drugs Health Pharma

Person in Mexico dies after contracting avian influenza, WHO says

A 59-year-old person in Mexico died in April after contracting avian influenza A(H5N2) virus, the first such death in the country, according to

Read More
The advisory committee of the US Food and Drug Administration has rejected a therapy using party drug MDMA, or ecstasy or molly to treat post-traumatic stress disorder.
Drugs Health Pharma

FDA advisers reject psychedelic party drug MDMA to treat PSTD in adults

The advisory committee of the US Food and Drug Administration has rejected a therapy using party drug MDMA, or ecstasy or molly to

Read More
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More